Stem cells from umbilical cord blood may help treat AD


Data suggest that the infusion of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) might be an effective therapy for patients with moderate-to-severe atopic dermatitis (AD), researchers reported online in Stem Cells (June 3, 2016).

In order to establish the safety and efficacy of hUCB-MSCs in AD, 34 adult patients with moderate-to-severe AD were enrolled in two trials with a follow-up of one month and three months, respectively.

The researchers reported that the study participants were randomly allocated to receive a low dose (2.5 x 107) or high dose (5.0 x 107) of hUCB-MSCs subcutaneously.

Findings revealed that a single treatment of hUCB-MSCs resulted in dose-dependent improvements in manifestations of AD, the authors wrote.

Additional data indicated that 55% of patients in the high dose hUCB-MSC-treated group showed a 50% reduction in the Eczema Area and Severity Index score. The investigator’s global assessment score and the Severity Scoring for Atopic Dermatitis score decreased by 33% and 50%, respectively, in the group treated with the high dose.

The investigators also reported that the administration of high dose hUCB-MSCs reduced the pruritus score by 58%. Serum IgE levels and number of blood eosinophils were down-regulated by the treatment.

“This study is a first-in-class study demonstrating that adults with moderate-to-severe atopic dermatitis responded to a treatment of stem cells derived from umbilical cord blood,” said Dr. Tae-Yoon Kim, senior author of the study, who was quoted in a press release.

“The single treatment of stem cells in patients resulted in the significant and persistent improvement in disease symptoms throughout the follow-up period of 12 weeks,” added Dr. Kim, a professor in the department of dermatology at The Catholic University of Korea in South Korea.

#atopicdermatitis #Dermatology #treatment #stemcells

4 views0 comments

Recent Posts

See All

Registration still open for Scleroderma Summit

Tomorrow, May 29, 2021, Chronicle Companies, in collaboration with Mallinckrodt Pharmaceuticals and Scleroderma Canada, is presenting the first Canadian Scleroderma Summit. The meeting will run from 1